Safety investigation of cytokine induced killer cell therapy in patients with malignant tumor
10.3969/j.issn.1000-484X.2015.12.015
- VernacularTitle:细胞因子诱导的杀伤细胞治疗恶性肿瘤安全性分析
- Author:
Junjie HOU
;
Duo LIU
;
Zhiqiang NI
;
Ying ZHOU
;
Ying YANG
;
Yanqiu FANG
;
Yan. TAN
- Publication Type:Journal Article
- Keywords:
Cytokine-induced killer cells;
Adverse reaction;
Cytokine;
Lymphocyte
- From:
Chinese Journal of Immunology
2015;31(12):1654-1658
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the adverse reactions of killer cytokine-induced (CIK) in the treatment of malignant tumor and to analyze the possible mechanism ,and to develop the targeted prevention and treatment measures .Methods: The clinical data, including various adverse reactions , laboratory tests and the corresponding preventive measures against adverse reactions .In 1 240 patients with malignant tumor after treated with CIK cells from May 2013 to September 2015 were retrospectively analyzed .Results:The main adverse reactions after the first infusion of CIK cells were weak (10%),fever(7.25%),shiver (4%),arthralgia (3%),systemic in flammatory response syndrome reaction ( 3%) , digestive tract discomfort ( 0.96%) , acute allergic reaction ( 0.08%) , rash (0.08%),angina pectoris (0.08%),tumor lysis syndrome(0%),infection(0%).With the increase of the treatment ,the incidence of adverse reactions increased and the fever was the main performance ,after the fourth course into the platform .The combination of blood pressure increased or decreased and severe allergic reaction and systemic inflammatory response syndrome was needed to be treated .The CIK cells were pretreated before treatment could reduce the incidence of these reactions .Conclusion:CIK cells therapy is a safe and effective adoptive immunotherapy for malignant tumor and its adverse reactions can be treated expectantly , but rare adverse reactions may have potential risks .
